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Purpose: The details of breast reconstruction and radiation therapy (RT) vary between institutions; therefore, we 
sought to investigate the practice patterns of radiation oncologists who specialize in breast cancer. 
Materials and Methods: We identified the practice patterns and inter-hospital variations from a multi-center co-
hort of women with breast cancer who underwent post-mastectomy RT (PMRT) to the reconstructed breast at 16 
institutions between 2015 and 2016. The institutions were requested to contour the target volume and produce 
RT plans for one representative case with five different clinical scenarios and answer questionnaires which elicited 
infrastructural information. We assessed the inter-institutional variations in RT in terms of the target, normal or-
gan delineation, and dose-volume histograms. 
Results: Three hundred fourteen patients were included; 99% of them underwent immediate reconstruction. The 
most irradiated material was tissue expander (36.9%) followed by transverse rectus abdominis musculocutaneous 
flap (23.9%) and silicone implant (12.1%). In prosthetic-based reconstruction with tissue expander, most patients 
received PMRT following partial deflation. Conventional fractionation and hypofractionation RT were used in 
66.6% and 33.4% patients, respectively (commonest: 40.05 Gy in 15 fractions [17.5%]). Furthermore, 15.6% of 
the patients received boost RT and 53.5% were treated with bolus. Overall, 15 physicians responded to the ques-
tionnaires and six submitted their contours and RT plans. There was a significant variability in target delineations 
and RT plans between physicians, and between clinical scenarios. 
Conclusion: Adjuvant RT following post-mastectomy reconstruction has become a common practice in Korea. The 
details vary significantly between institutions, which highlights an urgent need for standard protocol in this clini-
cal setting. 
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Introduction 
Breast reconstruction has become very common over the last two 
decades [1,2]. It significantly improves the quality of life and reduces 
adverse psychosocial effects following mastectomy [3]. However, the 
decision regarding breast reconstruction becomes complicated in pa-
tients who anticipate to receive post-mastectomy radiation therapy 
(PMRT) [4]. The majority of radiation oncologists believe that their 
ability to deliver radiotherapy to the chest wall is challenged by im-
mediate breast reconstruction [5]. Simultaneously, the majority of 
reconstructive surgeons believe that the cosmetic outcomes of breast 
reconstruction are negatively affected by PMRT [6,7]. 
Reconstructions can either be immediate or delayed or a com-
bined approach called delayed-immediate reconstruction [8]. An 
implant, autologous tissue or a combination of an implant and a 
flap, can be used for the restoration of the breast mound [9]. All 
reconstruction approaches have their own pros and cons [10,11]. 
The techniques available for radiotherapy delivery in patients 
with breast cancer who have undergone reconstruction have im-
proved over the past decade, which has reduced the challenges in 
radiotherapy planning that once seemed difficult to overcome. 
Despite the improvements in both reconstruction and radiothera-
py techniques, several issues still require to be answered, such as 
the type of reconstruction that is the most feasible with PMRT, 
the timing of reconstruction relative to PMRT, and optimization 
of radiotherapy to minimize treatment-related complications 
without compromising the oncological and cosmetic outcomes. 
The practice patterns may vary between institutions regarding 
the reconstruction type and radiotherapy planning and delivery. 
However, there are no standard protocols or guidelines in clinical 
settings. Therefore, the aim of this study was to investigate the 
practice patterns of PMRT in breast reconstruction in Korea. 
Materials and Methods 
1. Ethical statement 
After approval from the review board of the Korean Radiation On-
cology Group (KROG 18-04) and Severance Hospital Institutional 
Review Board (No. 4-2017-0931), a retrospective multi-center ob-
servational study and a dummy run study were conducted in pa-
tients with breast cancer who received RT and underwent breast 
reconstruction to identify the practice patterns. 
2. Observational study 
The inclusion criteria were as the following: histologically proven 
breast cancer, non-metastatic disease, female sex, and breast re-
construction following mastectomy and subsequent adjuvant RT 
between 2015 and 2016. The reconstruction rate has increased 
since 2015 after reimbursement by the Korean National Insurance 
Service and we surmised that it was actively performed during this 
period. Patients who underwent bilateral mastectomy for bilateral 
breast cancer or were male sex, or lost to follow-up were exclud-
ed. The medical charts of the patients were collected and retro-
spectively reviewed after approval from each participating center. 
The following parameters were analyzed: age, body mass index, 
smoking history, history of diabetes, clinical T and N stages, mul-
ticentricity, systemic therapy, mastectomy (standard, skin-sparing, 
and nipple-sparing), resection margin (clear, close, and positive), 
reconstruction sequence (one-stage vs. two-stage), reconstruc-
tion timing (immediate vs. delayed), reconstruction options (au-
tologous-based vs. prosthetic-based), reconstruction material at 
the time of RT (tissue expander, implant, transverse rectus ab-
dominis musculocutaneous flap, deep inferior epigastric perfora-
tor flap, latissimus dorsi flap, and others), bilateral reconstruction, 
operation time, RT technique (three-dimensional conformal, field-
in-field, step-and-shot intensity-modulated radiotherapy, and 
volumetric arc therapy), RT dose/fraction, estimated maximum 
dose in chest wall on RT planning system, chest wall boost RT, 
bolus material used, and use of regional RT (Table 1). 
3. Dummy run study 
The institutions participating in the Division of Breast Cancer, 
KROG were invited to participate in the present dummy run. They 
were requested to answer questionnaires (Supplementary A) re-
garding the infrastructural information, which included computed 
tomography (CT) simulation, radiation treatment planning (RTP) 
system, RT treatment details, and quality assurance (QA) activity 
for the RT machine. CT images from one anonymized patient was 
provided as a representative case with five different clinical sce-
narios (cases 1–5) (Supplementary Fig. S1). The physicians from the 
participating institutions downloaded these CT images from a web-
site and registered them in their own RTP systems; subsequently, 
they designed RT treatment plans for each clinical scenario. The 
target range, dose prescription, treatment technique, and beam in-
formation were obtained through the questionnaire. RT files in the 
Digital Imaging and Communications in Medicine (DICOM) format 
for the structure sets and radiation doses were submitted along 
with the questionnaires. 
4. Data analysis 
All analyses were performed using IBM SPSS Statistics version 25.0 
for Windows (IBM Corp., Armonk, NY, USA) using two-sided statis-
tical tests. Descriptive analyses were performed using Microsoft 
Excel 2010 (Microsoft Corporation, Redmond, WA, USA). 
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the same study period, approximately 1,105 patients were referred 
for PMRT. Table 2 and Fig. 1 present the details of the reconstruction 
treatments. Most of the patients (99%) underwent immediate recon-
struction. One-stage or autologous reconstruction was more fre-
quent than two-stage or prosthetic reconstruction when PMRT was 
administered. A variety of materials were used for the reconstruction. 
The most commonly used material was tissue expander (36.9%) fol-
lowed by TRAM flap (23.9%), silicone implant (12.1%), and a combi-
nation of tissue expander and silicone implant (11.2%). When tissue 
expander was used in prosthetic-based reconstruction, most patients 
(39.2%) received PMRT after partial deflation. Table 3 presents the 
details of radiotherapy. Conventional fractionation RT was used in 
66.6% of the patients, while hypofractionation was used in 33.4% of 
patients (commonest: 40.05 Gy in 15 fractions [17.5%]). Additionally, 
15.6% of the patients received boost RT and 53.5% of the patients 
were treated with a bolus.  
2. Dummy run and questionnaire  
Overall, 15 physicians responded to the questionnaires and six phy-
sicians submitted their contours and RT plans (Fig. 1). According to 
the questionnaires, the prescribed dosage varied between physi-
cians’. Generally, conventional fractionation with 50–50.4 Gy and 
Table 1. Baseline characteristics (n = 314)
Characteristic Value
Age (yr) 43.5 ±  8.3
 <40 116 (36.9)
 ≥40 198 (63.1)
BMI (kg/m2) 22.6 ±  3.3
Smoking
 Current 4 (1.3)
 Ever 4 (1.3)
 No 299 (95.2)
 Unknown 7 (2.2)
Diabetes mellitus
 No 300 (95.5)
 Yes 14 (4.5)
Clinical T stage
 T1 70 (22.3)
 T2 152 (48.4)
 T3 61 (19.4)
 T4 27 (8.6)
 Unknown 4 (1.3)
Clinical N stage
 N0 51 (16.2)
 N+ 260 (82.8)
 Unknown 3 (0.6)
Multicentricity
 No 187 (59.6)
 Yes 126 (40.1)
 Unknown 1 (0.3)
Systemic Tx
 Neoadjuvant chemo 165 (52.5)
 Adjuvant chemo 187 (59.6)
 Endocrine Tx 230 (73.2)
 Anti-HER2 Tx 125 (39.8)
Mastectomy
 Standard total 163 (51.9)
 Skin sparing 74 (23.6)
 Nipple sparing 77 (24.5)
Resection margin
 Complete 276 (87.9)
 Close 23 (7.3)
 Positive 12 (3.8)
 Unknown 3 (1.0)
Values are presented as median ± standard deviation or number (%).
BMI, body mass index; Tx, treatment; HER2, human epidermal growth 
factor receptor 2.
Results 
1. Observational study 
Overall, 314 patients treated with PMRT for reconstructed breasts 
between 2015 and 2016 at the 16 institutions were included. During 
Table 2. Reconstruction treatments (n = 314)
Variable Value
Reconstruction stage
 One-stage 160 (51.0)
 Two-stage 154 (49.0)
Reconstruction timing
 Immediate 312 (99.4)
 Delayed 2 (0.6)
Reconstruction type
 Prosthetic-based 190 (60.5)
 ADM use 171 (54.5)
 Autologous-based 122 (23.0)
 Both 2 (0.6)
Reconstruction status at the time of RT
 Tissue expander 116 (36.9)
 TRAM 75 (23.9)
 Silicone implant 39 (12.0)
 DIEP 29 (9.2)
 LD 12 (3.8)
 Others 43 (14.0)
Bilateral reconstruction, yes 34 (10.8)
Operation time (hr) 4.8 ±  3.1
Values are presented as number (%) or median ± standard deviation.
ADM, acellular dermal matrix; RT, radiotherapy; TRAM, transverse rectus 
abdominis myocutaneous; DIEP, deep inferior epigastric perforator; LD, 
latissimus dorsi.
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over 25–28 fractions was the commonest practice. In a case where 
a patient was diagnosed with initial clinical internal mammary 
node metastasis (case 3), one physician responded with prescrip-
tion of boost dose of 10 Gy in 5 fractions to the internal mammary 
node after 50 Gy in 25 fractions. Another physician responded with 
a total dose of 52.8 Gy in 16 fractions with simultaneous integrat-
ed boost technique to the internal mammary node. In a case where 
a patient presented with positive surgical resection margin (case 5), 
one physician responded with prescription of 54 Gy (Fig. 2). In the 
questionnaire-based study, 62.5% of physicians replied that they 
would prescribe boost dose. The most common boost doses that 
were prescribed included 10 Gy in 5 fractions and 14.4 Gy in 8 
fractions. Furthermore, 58.7% of physicians responded that they 
preferred to not use bolus in their treatments. However, 90% re-
sponded that they would use bolus for the patient with positive 
surgical resection margins (case 5) (Fig. 3). 
In terms of target volume delineation, the structures included in 
the target volume varied significantly between physicians, even 
within the same clinical scenario (Figs. 4 and 5; Supplementary Fig. 
S1). In a case where the patient was diagnosed with initial clinical 
internal mammary node metastasis (case 3), 13/15 physicians includ-
ed the internal mammary node in the target volume. In a case of the 
patient who underwent pre-pectoral reconstruction instead of sub-
pectoral reconstruction (case 4), 11/15 physicians included the tissue 
expander in the target volume. The dose-volume histograms were 
also analyzed. As for the planning target volume (PTV), it varied 
widely between physicians’ plans, even within the same clinical sce-
nario. The median PTV volume was 563.67 mL (range, 278.84 to 
1,100.77 mL; standard deviation [SD], 209.05 mL). Similarly, there 
was a wide difference in the mean lung dose; the median mean lung 
dose was 13.26 Gy (range, 5.33 to 18.80 Gy; SD, 4.60 Gy). There was 
also a wide variance in terms of lung V5 and V20; their median val-
ues were 43.89 mL (range, 16.35 to 99.45 mL; SD, 26.64 mL), 23.65 
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Fig. 1. Reconstruction details. (A) One-stage vs. two-stage reconstruction. (B) Prosthetic vs. autologous reconstruction. (C) Materials used for 
reconstruction. (D) Inflation status of the tissue expander at the time of radiation therapy. TRAM, transverse rectus abdominis myocutaneous; 
DIEP, deep inferior epigastric perforator; LD, latissimus dorsi; TUG, transverse upper gracilis; IGAP, inferior gluteal artery perforator; SIEA, super-
ficial inferior epigastric artery; PAP, profunda artery perforator.
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Table 3. Radiation treatments (n = 314)
Variable Value
Simulation position
 Supine 305 (97.1)
 Prone 2 (0.6)
 Unknown 7 (2.2)
RT technique
 Forward IMRT (field-in-field) 124 (39.5)
 Arc-IMRT 90 (28.7)
 Tangent, 3D 58 (18.5)
 Static-IMRT 26 (8.3)
 Helical tomo 8 (2.5)
 2D (tangential) 1 (0.3)
 Unknown 7 (2.2)
Fractionation
 Conventional 209 (66.6)
 Hypofractionation 105 (33.4)
 Use of boost RT, yes 49 (15.6)
 Boost RT dose (Gy) 9 ±  3.8
Expander status
 Full deflation 4 (1.3)
 Partial deflation 123 (39.2)
 Full inflation 13 (4.1)
Use of bolus
 No 146 (46.5)
 Yes 168 (53.5)
 Bolus off timing (Gy) 34.2 ±  14.6
Use of regional RT
 No 18 (5.7)
 AXL 7 (2.2)
 SCL 52 (16.6)
 IMN 1 (0.3)
 AXL + SCL 74 (23.6)
 AXL + IMN 1 (0.3)
 SCL + IMN 4 (1.3)
 AXL + SCL + IMN 157 (50.0)
Values are presented as number (%) or median ± standard deviation.
IMRT, intensity-modulated radiotherapy; RT, radiotherapy; AXL, axillary 
lymph node; SCL, supraclavicular lymph node; IMN, internal mammary 
node.
Discussion and Conclusion 
According to the Korean Breast Cancer Society (KBCS) registry, the 
number of breast reconstruction surgeries has increased almost 
3-fold between 2002 and 2013 [12]. In the 2017 KBCS report, the 
rate of reconstruction after mastectomy was 39.1%, 33.7%, and 
9.4% in those in the age-group of <40, 40–59, and ≥60 years, re-
spectively [13]. In the present study, approximately one-third of 
patients who underwent PMRT underwent breast reconstruction 


































































Fig. 2. Dose prescriptions according to different clinical scenarios.
Bolus
Fig. 3. Details of bolus application.
in the treatment of women with breast cancer who undergo recon-
struction and PMRT is to minimize the complications without com-
promising the oncological outcomes. Therefore, understanding the 
practice patterns is crucial for the communication between the pa-
tients and surgeons. To our knowledge, this is the first study to re-
port the practice patterns of PMRT in the setting of breast recon-
struction in Korea. 
Both RT techniques and breast reconstruction techniques have 
evolved over time. In the present study, a majority of the patients 
underwent immediate reconstruction; the rate of one-stage, two-
stage, autologous-based, and prosthetic-based reconstruction was 
51%, 49%, 23%, and 60.5%, respectively. The selection of the re-
construction material is individualized for each patient based on 
several patient, anatomical, and disease-specific factors, such as 
comorbidities, shape and size of the breast, availability of tissue 
around the breast and other donor sites, and planned adjuvant 
therapy. However, as presented in Fig. 1, we observed wide in-
https://doi.org/10.3857/roj.2020.00738240




































Fig. 4. Structures included in target volume delineation according to different clinical scenarios. AXL, axillary lymph node; SCL, supraclavicular 
lymph node; IMN, internal mammary node.
Fig. 5. Sum of all the radiation therapy structures included according to each clinical scenario. (A) Supraclavicular level. (B) Axillary level. (C) 
Upper reconstructed breast level. (D) Reconstructed breast level.
reconstruction dominantly influenced the decision-making regard-
ing the same. Considering that the thickness of post-mastectomy 
spared skin flap is one of the major determinants of one-stage im-
mediate reconstruction and the rate of reconstruction complica-
tions, the choice of breast reconstruction can also be affected 
based on whether a patient underwent skin-sparing mastectomy. 
According to a survey in the United States, implant-based recon-
struction was highly utilized in the setting of bilateral mastectomy 
[14]. Similarly, there have been substantial developments in the use 
of implant-based techniques and decrease in the use of autologous 
reconstruction materials. 
In the setting of prosthetic reconstruction, 87.9% of patients in 
the current study underwent partial deflation of the tissue expand-
ers before RT and only 9.3% had full inflation during RT, which was 
in contrast to the practice patterns in the United States where 
75.2% of the respondents specified that they do not routinely de-
Table 4. Dose volume histograms in the same representative case
Variable Value
PTV (mL) 563.67 (278.84–1,100.77)
Contralateral breast mean dose (Gy) 1.83 (0.03–9.48)
Skin Dmax (Gy) 47.95 (36.56–57.05)
Mean lung dose (Gy) 13.26 (5.33–18.80)
Mean heart dose (Gy) 5.08 (0.08–27.3)
LAD dose (Gy) 9.91 (0.08–32.06)
Lung V5 (mL) 43.89 (16.35–99.45)
Lung V10 (mL) 38.21 (12.67–81.89)
Lung V20 (mL) 23.65 (6.70–34.03)
Values are presented as median (range).
PTV, planning target volume.
ter-hospital variability in the use of breast reconstruction material, 
which reflected that the hospital where a patient underwent the 
B DA C
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flate the expander before RT [15]. Given that recent retrospective 
studies from Korea reported that maximal inflation status at the 
time of RT was significantly associated decreased risk of recon-
struction-related complications [16], this issue needs to be dis-
cussed with reconstructive surgeons and investigated further in the 
future. 
Interestingly, we found more heterogeneity in the details regard-
ing radiation. Firstly, two-thirds of the patients were treated with 
conventional fractionation while a few large-volume hospitals pre-
ferred hypofractionation RT schedules with various regimens. Data 
supporting hypofractionation RT following mastectomy are still 
very limited, especially, when accompanied by breast reconstruc-
tion [17]. In 2019, we previously reported that hypofractionation 
RT (40 Gy in 15 fractions) may mitigate the risk of complications in 
two-stage prosthetic breast reconstruction [18]. Currently, several 
randomized trials—Alliance A221505 (NCT03414970), FABREC 
(NCT03422003)—are underway to investigate the role of hypofrac-
tionation RT in reconstructed breasts. Secondly, the use of boost RT 
was underutilized in the present cohort (15.6%) in contrast with a 
US survey in 2014, in which 66.5% of respondents indicated that 
they would prescribed boost RT [15]. A recent study from Harvard 
suggests that boost RT was significantly associated with recon-
struction-related complications and reconstruction failure and that 
it does not improve local tumor control [19]; therefore, routine use 
of boost RT should be avoided and risk-to-benefit assessment is 
recommended. Bolus was applied in 53.5% of the patients, which 
is similar to the results of the US survey in which a majority of re-
spondents (52.2%) stated that bolus is used in the setting of tissue 
expanders [15]. 
The most interesting finding of the present study is the startling 
variability in the target delineation and RT plans between physi-
cians as well as clinical scenarios (Fig. 5; Supplementary Fig. S1). In 
contrast to field-based PMRT techniques, in volume-based RT plan-
ning, the variations in the target could significantly influence 
RT-related toxicities and/or oncological outcomes. In this context, 
the European Society for radiotherapy and Oncology–Advisory 
Committee in Radiation Oncology Practice (ESTRO–ACROP) pre-
sented multidisciplinary consensus-based target volume guidelines 
in the setting of PMRT after implant-based immediate reconstruc-
tion [20,21] that could play an important role in reducing the in-
ter-physician variability. 
There are several limitations to this study. First, the current study 
did not represent the whole population of Korea. Despite the best 
efforts, 16 institutions participated in this study and only six physi-
cians completed the final submission for the dummy run study. 
Second, this cross-sectional study only included data of 2 years; 
therefore, a follow-up study is needed to identify further findings. 
Third, the data regarding reconstruction in patients who did not re-
ceive PMRT was lacking and, hence, the generalization of these 
findings to all breast reconstruction practices in Korea is limited. 
Reconstruction complications and their predictors will be discussed 
in another article. 
In conclusion, in Korea, breast reconstruction has become an im-
portant consideration in the multidisciplinary management of pa-
tients with breast cancer due to the importance of the psychosocial 
functions of the symmetric breast mound. Our study’s findings re-
garding the variability in reconstruction and PMRT details, there-
fore, provide valuable information to physicians and patients. As 
the reconstructive and therapeutic options become more sophisti-
cated, this balance will be on the forefront of further cancer treat-
ment. Multidisciplinary collaboration between radiation oncolo-
gists, surgical oncologists, plastic surgeons, and medical oncologists 
is imperative to deliver the best care to our patients. Our multi-cen-
ter prospective observational study (NCT03523078) is underway to 
evaluate patient satisfaction and cosmetic outcomes according to 
breast reconstruction and different type of PMRT.  
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